Contents:

1 Executive Summary 2 About Cancer Highlights 3 Methodologies 4 Table of Contents 4.1 List of Figures 4.2 List of Tables 5 Introduction 6 Single Drug Target Benchmarking from the Leukemia Pipeline 6.1.1 Carboxy-Lyase Activity Targets 6.1.2 Catalytic Activity Targets 6.1.3 Cell Adhesion Molecule Activity Targets 6.1.4 Chaperone Activity Targets 6.1.5 Cysteine-Type Peptidase Activity Targets 6.1.6 Cytokine Activity Targets 6.1.7 Deaminase Activity Targets 6.1.8 DNA Repair Protein Targets 6.1.9 DNA Topoisomerase Activity Targets 6.1.10 DNA-Directed DNA Polymerase Activity Targets 6.1.11 DNA-Methyltransferase Activity Targets 6.1.12 G-Protein Coupled Receptor Activity Targets 6.1.13 Growth Factor Activity Targets 6.1.14 Hydrolase Activity Targets 6.1.15 Kinase Activity Targets 6.1.16 Kinase Regulator Activity Targets 6.1.17 Ligand-Dependent Nuclear Receptor Activity Targets 6.1.18 Ligase Activity Targets 6.1.19 Lipid Kinase Activity Targets 6.1.20 MHC Class I Receptor Activity Targets 6.1.21 Molecular Function Unknown Targets 6.1.22 Motor Activity Targets 6.1.23 Oxidoreductase activity Targets 6.1.24 Phosphoric diester hydrolase activity Targets 6.1.25 Phosphorylase activity Targets 6.1.26 Protein Binding Targets 6.1.27 Protein serine/threonine kinase activity Targets 6.1.28 Protein tyrosine phosphatase activity Targets 6.1.29 Protein-tyrosine kinase activity Targets 6.1.30 Receptor Activity Targets 6.1.31 Receptor Signaling Complex Scaffold Activity Targets 6.1.32 RNA Binding Targets 6.1.33 RNA-Directed DNA Polymerase Activity Targets 6.1.34 Serine-Type Peptidase Activity Targets 6.1.35 Structural Constituent Of Cytoskeleton Targets 6.1.36 Superoxide dismutase activity Targets 6.1.37 T Cell Receptor Activity Targets 6.1.38 Transcription Factor Activity Targets 6.1.39 Transcription Regulator Activity Targets 6.1.40 Transferase Activity Targets 6.1.41 Translation Regulator Activity Targets 6.1.42 Transmembrane receptor activity Targets 6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 6.1.44 Transporter activity Targets 6.1.45 Other Targets 6.2 The Cancer Genome Project and Leukemia Targets 6.2.1 Leukemia Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 6.3 Structure-based Drug Design in Leukemia is Stimulated by Available Structure Data on Biological Targets 6.4 Target-Target Interactions among Identified Leukemia Targets 6.5 The Drug-Target Interactome 6.6 Protein Expression Levels of Identified Drug Targets of Leukemia Drugs 6.7 Pathway Analysis of Leukemia Drug Targets 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline? 7.1 Pre-Registration to being Marketed: New and Unique Drug Target Combinations of the Leukemia Pipeline 7.2 Phase III Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 7.3 Phase II Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 7.4 Phase I Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 7.5 Preclinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline 7.6 Development Profiles of All Leukemia Drug Target Combinations 8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound 8.1 Small Molecules 8.1.1 Background 8.1.2 Targets in Leukemia 8.2 Peptide/Protein Drugs 8.2.1 Background 8.2.2 Targets in Leukemia 8.3 Antibodies and Antibody-like Structures 8.3.1 Background 8.3.2 Targets in Leukemia 8.4 Nucleic Acid Therapies 8.4.1 Background 8.4.2 Targets in Leukemia 8.5 Gene Therapy 8.5.1 Background 8.5.2 Targets in Leukemia 8.6 Drug Delivery and Nanotechnology 8.6.1 Background 8.6.2 Targets in Leukemia 8.7 Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets 9 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator 9.1 4SC 9.2 Abbott 9.3 Abiogen 9.4 Actinium Pharmaceuticals 9.5 AEgera 9.6 Aeterna Zentaris 9.7 Agennix 9.8 Alexion 9.9 Alfa Wassermann 9.10 Ambit Biosciences 9.11 Amgen 9.12 Antigenics 9.13 Antisoma 9.14 Ariad 9.15 Arno Therapeutics 9.16 Array BioPharma 9.17 Asahi Kasei Pharma 9.18 Ascenta Therapeutics 9.19 Astellas 9.20 Astex Therapeutics 9.21 AstraZeneca 9.22 Attenuon 9.23 Bayer 9.24 BioCryst Pharmaceuticals 9.25 Biogen Idec 9.26 Bioton 9.27 Boehringer Ingelheim 9.28 Bristol-Myers Squibb 9.29 BTG 9.30 Calistoga Pharmaceuticals 9.31 Callisto Pharmaceuticals 9.32 Celator Pharmaceuticals 9.33 Cell Genesys 9.34 Cell Therapeutics 9.35 Cephalon 9.36 CJ Corp 9.37 Clavis Pharma 9.38 Curacyte 9.39 Cyclacel 9.40 Cylene Pharmaceuticals 9.41 CytImmune Sciences 9.42 Cytokinetics 9.43 Daiichi Sankyo 9.44 Dainippon Sumitomo Pharma 9.45 Dara Biosciences 9.46 Deciphera Pharmaceuticals 9.47 Dong-A 9.48 Eleos 9.49 Eli Lilly 9.50 Enzon 9.51 EpiCept 9.52 Exelixis 9.53 ExonHit Therapeutics 9.54 Gemin X Pharmaceuticals 9.55 Genentech 9.56 Genmab 9.57 Genta 9.58 Genzyme 9.59 Geron 9.60 GlaxoSmithKline 9.61 Gloucester Pharmaceuticals 9.62 GlycoGenesys 9.63 Hayashibara 9.64 Hoffmann-La Roche 9.65 ImClone Systems 9.66 Immunomedics 9.67 Innate Pharma 9.68 Innovive 9.69 Isis Pharmaceuticals 9.70 Italfarmaco 9.71 Johnson & Johnson 9.72 Kanisa 9.73 Kyowa Hakko Kirin 9.74 LG Life Sciences 9.75 Lorus Therapeutics 9.76 MAT Biopharma 9.77 MaxCyte 9.78 Meda 9.79 Medarex 9.80 MethylGene 9.81 Micromet 9.82 MorphoSys 9.83 NanoMed Pharmaceuticals 9.84 Nerviano Medical Sciences 9.85 National Institute of Health (USA) 9.86 Nippon Shinyaku 9.87 Novartis 9.88 Novogen 9.89 PDL BioPharma 9.90 Peplin 9.91 Pfizer 9.92 Pharmacyclics 9.93 PharmaMar 9.94 PIERIS Proteolab 9.95 Rigel 9.96 Sanofi-Aventis 9.97 Santaris Pharma 9.98 SBIO 9.99 Schering-Plough 9.100 SciGen 9.101 Seattle Genetics 9.102 Sepal Pharma 9.103 Servier 9.104 Shantha Biotechnics 9.105 Sidus 9.106 Spirogen 9.107 Stemline Therapeutics 9.108 SuperGen 9.109 Supratek Pharma 9.110 Swedish Orphan 9.111 SymBio Pharmaceuticals 9.112 Takeda 9.113 Teva 9.114 TopoTarget 9.115 Trion Pharma 9.116 Trubion 9.117 Vertex Pharmaceuticals 9.118 Vion Pharmaceuticals 9.119 VioQuest 9.120 Wyeth 9.121 Yamasa Corporation 9.122 Zenyaku Kogyo 9.123 ZymoGenetics 9.124 Non-Industrial Sources 10 Disclaimer 11 Drug Index 12 Company Index 4.1 List of Figures Figure 1: Overall Breakdown of Included Leukemia Pipeline by Sub-indication and Stage of Development Figure 2: Visualization of Target-Target Interactions Among Leukemia Drug Targets Figure 3: The Drug-Protein Interactome of Leukemia Drugs – The Main Cluster Figure 4: The Drug-Protein Interactome of Leukemia Drugs – Smaller Clusters Figure 5: Head-to-Head Targeting Interactome of Leukemia Drugs Figure 6: Distribution of Compound Types among Leukemia Drugs Figure 7: Primary Sub-cellular Localization of Drug Targets 4.2 List of Tables Table 1: Overview of Drug Target Profile Themes Table 2: Drug Targets of Leukemia Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census Table 3: Identity of Leukemia Drug Targets with Available Biological Structures Table 4: Number of Target-Target Interactions among Leukemia Drug Targets Table 5: Drug-Protein Interactome Clusters Table 6: Leukemia Drug Targets with Available Protein Expression Profiles Table 7: Pathway Summary Table 8: Drug Targets without any Identified Assigned Pathways Table 9: Pathway Profile According to BioCarta of Leukemia Drug Targets Table 10: Pathway Profile According to KEGG of Leukemia Drug Targets Table 11: Pathway Profile According to NetPath of Leukemia Drug Targets Table 12: Number of Drug Target Combinations by the Highest Developmental Stage and Uniqueness Table 13: Top 5 Competitive Leukemia Targets Table 14 New and Unique Leukemia Targets in Pre-Registration to Marketed Table 15: New and Unique Leukemia Targets in Phase III Clinical Development Table 16: New and Unique Leukemia Targets in Phase II Clinical Development Table 17 New and Unique Leukemia Targets in Phase I Clinical Development Table 18: New and Unique Leukemia Targets in Preclinical Development Table 19: The Progression, Maturity and Competitive Comparison of Leukemia Drug Target Combinations in Development Table 20: Number of Leukemia Drug Target Mixes Reported by Compound Strategy Table 21: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Leukemia by Drug Target Table 22: Drug Targets of Small Molecule Drugs in Leukemia Table 23: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Leukemia Table 24: Drug Targets of Peptide Based Drugs in Leukemia Table 25: Drug Targets of Protein Based Drugs in Leukemia Table 26: Drug Targets of Antibodies and Antibody-like Drugs in Leukemia Table 27: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Leukemia . 312 Table 28: Drug Targets of Nucleic Acid Therapies in Leukemia Table 29: Vectors in Gene Therapy Table 30: Drug Targets of Gene Therapies in Leukemia Table 31: Drug Targets with New Drug Delivery Strategies in Leukemia Table 32: Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets Table 33: 4SC's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 34: Abbott's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 35: Abiogen's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 36: Actinium Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 37: AEgera's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 38: Aeterna Zentaris' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 39: Agennix's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 40: Alexion's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 41: Alfa Wassermann's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 42: Ambit Biosciences' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 43: Amgen's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 44: Antigenics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 45: Antisoma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 46: Ariad's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 47: Arno Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 48: Array BioPharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 49: Asahi Kasei Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 50: Ascenta Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 51: Astellas' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 52: Astex Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 53: AstraZeneca's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 54: Attenuon's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 55: Bayer's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 56: BioCryst Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 57: Biogen Idec's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 58: Bioton's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 59: Bioton's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 60: Bristol-Myers Squibb's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 61: BTG's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 62: Calistoga Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 63: Callisto Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 64: Celator Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 65: Cell Genesys' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 66: Cell Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 67: Cephalon's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 68: CJ Corp's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 69: Clavis Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 70: Curacyte's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 71: Cyclacel's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 72: Cylene Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 73: CytImmune Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 74: Cytokinetics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 75: Daiichi Sankyo's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 76: Dainippon Sumitomo Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out. 389 Table 77: Dara Biosciences' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 78: Deciphera Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 79: Dong-A's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 80: Eleos' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 81: Eli Lilly's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 82: Enzon's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 83: EpiCept's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 84: Exelixis' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 85: ExonHit Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 86: Gemin X Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 87: Genentech's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 88: Genmab's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 89: Genta's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 90: Genzyme's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 91: Geron's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 92: GlaxoSmithKline's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 93: Gloucester Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 94: GlycoGenesys' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 95: Hayashibara's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 96: Hoffmann-La Roche's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 97: ImClone Systems' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 98: Immunomedics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 99: Innate Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 100: Innovive's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 101: Isis Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 102: Italfarmaco's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 103: Johnson & Johnson's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 104: Kanisa's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 105: Kyowa Hakko Kirin's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 106: LG Life Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 107: Lorus Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 108: MAT Biopharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 109: MaxCyte's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 110: Meda's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 111: Medarex's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 112: MethylGene's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 113: Micromet's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 114: MorphoSys' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 115: NanoMed Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 116: Nerviano Medical Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 117: NIH's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 118: Nippon Shinyaku's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 119: Novartis' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 120: Novogen's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 121: PDL BioPharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 122: Peplin's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 123: Pfizer's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 124: Pharmacyclics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 125: PharmaMar's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 126: PIERIS Proteolab's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 127: Rigel's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 128: Sanofi-Aventis' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 129: Santaris Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 130: SBIO's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 131: Schering-Plough's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 132: SciGen's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 133: Seattle Genetics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 134: Sepal Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 135: Servier's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 136: Shantha Biotechnics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 137: Sidus' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 138: Spirogen's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 139: Stemline Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 140: SuperGen's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 141: Supratek Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 142: Swedish Orphan's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 143: SymBio Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 144: Takeda's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 145: Teva's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 146: TopoTarget's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 147: Trion Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 148: Trubion's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 149: Vertex Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 150: Vion Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 151: VioQuest's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 152: Wyeth's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 153: Yamasa Corporation's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 154: Zenyaku Kogyo's Included Leukemia Pipeline Composition and Competitive Fall-Out Table 155: ZymoGenetics' Included Leukemia Pipeline Composition and Competitive Fall-Out Table 156: Non-industrial Sources' Included Leukemia Pipeline Composition and Competitive Fall-Out

Companies Mentioned

- Abbott - Abiogen - Actinium Pharmaceuticals - AEgera - Aeterna Zentaris - Agennix - Alexion - Alfa Wassermann - Ambit Biosciences - Amgen - Antigenics - Antisoma - Ariad - Arno Therapeutics - Array BioPharma - Asahi Kasei Pharma - Ascenta Therapeutics - Astellas - Astex Therapeutics - AstraZeneca - Attenuon - Bayer - BioCryst Pharmaceuticals - Biogen Idec - Bioton - Boehringer Ingelheim - Bristol-Myers Squibb - BTG - Calistoga Pharmaceuticals - Callisto Pharmaceuticals - Celator Pharmaceuticals - Cell Genesys - Cell Therapeutics - Cephalon - CJ Corp - Clavis Pharma - Curacyte - Cyclacel - Cylene Pharmaceuticals - CytImmune Sciences - Cytokinetics - Daiichi Sankyo - Dainippon Sumitomo Pharma - Dara Biosciences - Deciphera Pharmaceuticals - Dong-A - Eleos - Eli Lilly - Enzon - EpiCept - Exelixis - ExonHit Therapeutics - Gemin X Pharmaceuticals - Genentech - Genmab - Genta - Genzyme - Geron - GlaxoSmithKline - Gloucester Pharmaceuticals - GlycoGenesys - Hayashibara - Hoffmann-La Roche - ImClone Systems - Immunomedics - Innate Pharma - Innovive - Isis Pharmaceuticals - Italfarmaco - Johnson & Johnson - Kanisa - Kyowa Hakko Kirin - LG Life Sciences - Lorus Therapeutics - MAT Biopharma - MaxCyte - Meda - Medarex - MethylGene - Micromet - MorphoSys - NanoMed Pharmaceuticals - National Institute of Health (USA) - Nerviano Medical Sciences - Nippon Shinyaku - Non-Industrial Sources - Novartis - Novogen - PDL BioPharma - Peplin - Pfizer - Pharmacyclics - PharmaMar - PIERIS Proteolab - Rigel - Sanofi-Aventis - Santaris Pharma - SBIO - SC - Schering-Plough - SciGen - Seattle Genetics - Sepal Pharma - Servier - Shantha Biotechnics - Sidus - Spirogen - Stemline Therapeutics - SuperGen - Supratek Pharma - Swedish Orphan - SymBio Pharmaceuticals - Takeda - Teva - TopoTarget - Trion Pharma - Trubion - Vertex Pharmaceuticals - Vion Pharmaceuticals - VioQuest - Wyeth - Yamasa Corporation - Zenyaku Kogyo - ZymoGenetics